SLC43A3 and glioblastoma: Interestingly, the expression of SLC43A3 increased with the pathological grade and was most highly expressed in the ME transcriptional subgroup, which has been associated with a malignant process and shorter median survival time in glioblastoma patients (Fig. 8F–I).